Cargando…
Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
AIMS: Cholinesterase inhibitors (CEIs) have been shown to improve cognitive functioning in Alzheimer's disease (AD) patients, but are associated with multiple side effects and only 20–40% of the patients clinically improve. In this study, we aimed to investigate the acute pharmacodynamic (PD) e...
Autores principales: | Baakman, Anne Catrien, Gavan, Carmen, van Doeselaar, Lotte, de Kam, Marieke, Broekhuizen, Karen, Bajenaru, Ovidiu, Camps, Laura, Swart, Eleonora L., Kalisvaart, Kees, Schoonenboom, Niki, Lemstra, Evelien, Scheltens, Philip, Cohen, Adam, van Gerven, Joop, Groeneveld, Geert Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306507/ https://www.ncbi.nlm.nih.gov/pubmed/34964149 http://dx.doi.org/10.1111/bcp.15206 |
Ejemplares similares
-
Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI
por: Leijenaar, Jolien F., et al.
Publicado: (2020) -
First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
por: Baakman, Anne C., et al.
Publicado: (2016) -
The case of galantamine: repurposing and late blooming of a cholinergic drug
por: Mucke, Hermann AM
Publicado: (2015) -
No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model
por: Baakman, Anne Catrien, et al.
Publicado: (2019) -
EEG machine learning for accurate detection of cholinergic intervention and Alzheimer’s disease
por: Simpraga, Sonja, et al.
Publicado: (2017)